| Literature DB >> 17129828 |
Abstract
Over the past five years there has been a surge of interest in using positron emission tomography (PET) to determine the in vivo density of the senile plaque, a key pathological feature of Alzheimer's disease. The development of the tracers [(11)C]-PIB, [(11)C]-SB13 and [(18)F]-FDDNP has coincided with drug strategies aimed at altering the brain metabolism of amyloid-beta peptides. The evolution of these novel ligands serves not only as an excellent example of how rapidly imaging technologies can progress but also as a reminder that the fundamental biological knowledge, which is necessary to fully interpret the PET data, can be left trailing behind.Entities:
Mesh：
Substances：
Year: 2006 PMID： 17129828 DOI： 10.1016/j.drudis.2006.10.008
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851